Background. Atrial natriuretic peptide (ANP) release is increased in patients with ischaemic left ventricular dysfunction. A bene®cial effect of naloxone on recovery from myocardial stunning was shown previously. The aim of this study was to investigate the effects of naloxone on ANP release during regional myocardial ischaemia and stunning in awake dogs.
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The natriuretic peptide family consists of a group of structurally similar but genetically distinct peptides. Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), both of myocardial origin, are reactive hormones whose elevated blood levels correlate with myocardial dysfunction, in the presence of cardiac failure. They are similarly upregulated in heart failure and counteract neurohormones that induce vasoconstriction and¯uid retention. 1 However, responses of the natriuretic peptides during regional myocardial ischaemia and stunning remain uncertain. Myocardial stunning is a general term for the mechanical dysfunction that persists after reperfusion even in the absence of irreversible damage and despite the return of normal, near-normal, or supranormal perfusion. 2 In a previous investigation, we demonstrated that naloxone attenuates myocardial stunning in conscious dogs through its action on the central nervous system. 3 This effect of naloxone might be explained by antagonizing endogenous opioid peptides (EOPs) which are released upon myocardial ischaemia and have negative inotropic properties.
are released in response to myocardial regional ischaemia and stunning and (2) that naloxone prevents this ischaemiainduced release.
Methods
This investigation is performed in accordance with the Guide for the Care and Use of Laboratory Animals 5 and was approved by the District Government of Mu Ènster. After overnight fasting, 10 mongrel dogs (either sex, weight 23±32 kg) received i.m. pre-medication with piritramide 1 mg kg ±1 and ketamine 5 mg kg ±1 . The animals were anaesthetized i.v. with propofol 5 mg kg ±1 . After tracheal intubation, anaesthesia was maintained with iso¯urane in a mixture of oxygen (35%) in air and supplemented by fentanyl (5 mg kg ±1 ). Perioperative antibiotic prophylaxis was achieved with cefamandole 30 mg kg ±1 . Details of the instrumentation methods have been published previously 6 and are summarized brie¯y belown. A left thoracotomy was performed at the ®fth intercostal space under aseptic conditions. Size 18 F gauge catheters were inserted into the descending aorta and the left atrium for pressure measurement, injection of microspheres, administration of naloxone, and withdrawal of blood. A pressure microtransducer (Janssen Pharmaceutica, Beerse, Belgium) was inserted into the left ventricle through an apical stab wound to measure left ventricular pressure (LVP). Pulsed Doppler blood¯ow velocity probes (20 MHz; Baylor College of Medicine, Houston, TX, USA) were ®tted around the left anterior descending coronary artery (LAD). To measure the regional myocardial wall-thickening fraction (WTF), 10 MHz pulsed Doppler crystals were sutured to the myocardium in the LAD-perfused area. Proximal to the Doppler¯ow probe, a pneumatic occluder was positioned around the LAD (proximal to the ®rst main diagonal branch) to induce reversible brief ischaemic episodes in the LADperfused myocardium. After closure of the thorax, all leads were tunnelled subcutaneously and exteriorized between the scapulae. After instrumentation, the animals were trained daily to accustom them to the experimental environment and to ensure that they could quietly lie in the cage when connected to the data acquisition system. Aortic and left atrial pressures were measured using disposable pressure transducers. Pressure,¯ow velocity, and wall-thickening signals were processed using a six-channel pulsed Doppler system (Baylor College of Medicine). The left ventricular micromanometer was calibrated to the pressures measured in the aorta and left atrium. The LVP signal was electronically differentiated (Gould Inc., Cleveland, OH, USA) to obtain LV dP´dt max ±1 and LV dP´dt min ±1 . All signals were digitally recorded. Experiments were only conducted after the animals had recovered completely from the instrumentation, and measurements of blood gas values and haemodynamic variables showed normal values, which took between 10 and 12 days after surgery.
Arterial blood samples for measurement of ANP and BNP were drawn from the aortic catheter, collected into chilled syringes and transferred to polypropylene tubes containing EDTA (1 mg ml ±1 of blood) and aprotinin (500 kIU ml ±1 of blood). Thereafter, the samples were centrifuged and the plasma stored at ±70°C until analysis. ANP and BNP plasma concentrations were analysed by radioimmunoassays using a polyclonal rabbit IgG-antisera raised to the following peptides (Peninsula Laboratories, Belmont, CA, USA): a-ANP 1±28 (human) and BNP-32 (human). Peptides were extracted from 3 ml plasma (Sep-Pak C 18 , Waters Associates, Milford, MA, USA) and eluted with 3 ml of a mixture of 60% acetonitrile, 0.1% tri¯uoroacetic acid, and 39% distilled water (by volume). All samples were assayed in triplicate. Standard curves were constructed with standard human ANP and BNP in radioimmunoassay buffer. The mean recovery of added natriuretic peptides from plasma was 60±80%, and the lower detection limits as de®ned by 95% of the upper plateau of the standard curve were 0.1 nmol per tube for ANP and 0.5 nmol per tube for BNP. Cross reactivity between natriuretic peptides was less than 0.1%. The intra-assay and inter-assay coef®cients of variation were 3.8 and 9.6% for ANP and 6.1 and 7.9% for BNP, respectively.
The experimental design was as follows: All 10 dogs were used in two ischaemic experiments. Each dog had one ischaemic episode without pre-treatment and the other ischaemic episode after pre-treatment with 63 mg kg ±1 naloxone (Curamed Pharma, GmbH, Ch.-B.: 0060697) i.v. 5 min before ischaemia. 3 Five animals received their ®rst coronary artery occlusion without pre-treatment. The other ®ve received naloxone before their ®rst ischaemia.
The following observations were made. 1. Measurement of baseline (BL) values in the awake state and induction of 10 min of LAD ischaemia, with follow-up of WTF, ANP, and BNP levels until complete recovery occurred. 2. Measurement of BL values in the awake state, application of 63 mg kg ±1 naloxone, induction of 10 min of LAD ischaemia, with follow-up of WTF, ANP, and BNP levels until complete recovery occurred. A second ischaemic episode was only induced when there was complete recovery of regional myocardial function in the LAD-perfused area; the minimum time interval between the two experiments was 4 days.
Regional myocardial blood¯ow was measured using coloured microspheres (Triton Technology, San Diego, CA, USA). For each measurement, a total of 9Q10 6 microspheres suspended in a volume of 3 ml 0.9% NaCl was injected into the left atrium. The reference blood sample was withdrawn from the aortic catheter at a rate of 10 ml min ±1 . Animals were killed by injection of potassium chloride into the LA catheter during general anaesthesia when regional myocardial function had completely recovered after the last ischaemic episode. The heart was dissected and three tissue samples were obtained from the LAD-perfused left ventricle in each dog. LAD samples were taken from the immediate vicinity of the wall-thickening probes. Only samples from animals with severe ischaemic dysfunction, as determined by the wall-thickening probe, were included (no animal was excluded due to insuf®cient dysfunction). Samples were further dissected into the subendocardial, subepicardial, and mid-myocardial layers. Measurement of microspheres in the tissue samples was performed as described previously. 7 Measurement of regional myocardial blood¯ow to the regions described was carried out four times during the experiment, as follows: (1) without naloxone and without ischaemia (control), (2) without naloxone during ischaemia, (3) after naloxone and without ischaemia, and (4) after naloxone and during ischaemia.
Experiments were conducted in chronically instrumented conscious dogs to avoid the effects of acute surgical trauma, anaesthesia, volume and ionic imbalances, and temperature on recovery from stunning. As multiple stun manoeuvres may induce extensive development of coronary collaterals thus precluding the induction of post-ischaemic dysfunction, the number of ischaemic episodes was restricted to two in each animal.
Statistical analysis
Data were analysed using repeated-measures two-way ANOVA followed by Bonferroni-corrected Student's t-test as appropriate; P<0.05 was considered signi®cant. Data are presented here as mean plus or minus standard error of the mean (SD).
Results
None of the animals was excluded from the analysis due to insuf®cient dysfunction. The maximum degree of regional ischaemic dysfunction was similar during the ®rst and the second ischaemic episodes in each dog.
ANP and BNP levels
Regional myocardial ischaemia in the LAD-perfused area caused a signi®cant release of ANP (Fig. 1A) only in the control without naloxone (peak levels: 182 (SD 30) vs 29 (7) pg ml ±1 at BL). Between 1 and 180 min of reperfusion, ANP levels were signi®cantly higher in the control (P<0.05) as compared with the experiment with naloxone pre-treatment. After naloxone pre-treatment, ANP levels remained unchanged during and after regional ischaemia. Myocardial BNP (Fig. 1B) release during regional ischaemia and reperfusion was not different between experiments with or without naloxone.
Arterial blood pressure, left atrial pressure, heart rate, LV dP´dt max ±1 , and LV dP´dt min
±1
There were no signi®cant changes in arterial pressure in either experimental group during or after ischaemia (Table  1) . Left atrial pressure during LAD ischaemia increased signi®cantly only in the control. Induction of regional ischaemia did not induce a signi®cant alteration of LV dP´dt max ±1 (Table 1) in the control. After naloxone pretreatment, LV dP´dt max ±1 was signi®cantly elevated during ischaemia and remained so until 30 min of reperfusion. After naloxone, LV dP´dt min ±1 was signi®cantly lower during ischaemia and remained so until 720 min of reperfusion, as compared with the control experiments ( Table 1) . Heart rate during LAD ischaemia increased signi®cantly in both experiments, but there was no signi®-cant difference between the two experiments during or after ischaemia.
Blood¯ow velocity in the LAD artery
During LAD occlusion, LAD¯ow velocity decreased to zero and increased to signi®cantly higher values compared with the BL for the ®rst 15 min during reperfusion (Table 1) . There were no statistically signi®cant differences between the experimental groups in blood¯ow velocity in the LADperfused area.
Regional myocardial wall thickening
In all animals, severe regional myocardial dysfunction occurred during LAD occlusion. Induction of regional ischaemia led to a signi®cant reduction in WTF to negative values (`wall thinning') in both experimental conditions (Fig. 2) . During ischaemia, WTF in the LAD-perfused area expressed as a percentage of the BL value was reduced to ±56 (13)% in the experiment with naloxone and to ±58 (14)% in the experiment without naloxone. During reperfusion, WTF in relation to pre-ischaemic BL recovered signi®cantly faster with naloxone as compared without naloxone at time points between 1 and 30 min of reperfusion (94 (10) vs 23 (39)% at 1 min; 99 (7) vs 33 (48)% at 5 min; 98 (6) vs 40 (50)% at 15 min; 94 (12) vs 47 (36)% at 20 min; and 92 (9) vs 49 (29)% at 30 min). After 30 min of reperfusion no signi®cant difference in WTF occurred. BL WTF values were reached after 48 h of reperfusion with and without naloxone.
Regional myocardial blood¯ow
During LAD occlusion, sub-endocardial blood¯ow decreased signi®cantly from 0.74 (0.24) to 0.08 (0.01) ml g ±1 min ±1 without (P<0.05 vs BL), and from 1.1 (0.19) to 0.1 (0.05) ml g ±1 min ±1 with naloxone (P<0.05 vs BL). Administration of naloxone in the absence of ischaemia led to a signi®cant increase in sub-endocardial blood¯ow to the LAD-perfused areas (0.74 (0.24) vs 1.1 (0.19) ml g ±1 min ±1 ). Without ischaemia, naloxone caused a signi®cant increase in the blood¯ow ratio between the sub-endocardial and the sub-epicardial regions (endocardial/epicardial ratio) in the LAD-perfused area (1.2 (0.74) vs 2.21 (1.04)). Blood ow ratio to the sub-endocardial layers between the occluded (LAD-perfused area) and the normal, nonischaemic zone (occluded/normal ratio) during ischaemia was not different with and without naloxone.
Discussion
In this chronically instrumented dog model ANP levels increased signi®cantly during regional LAD ischaemia and remained elevated during myocardial stunning. Pre-ischaemic administration of naloxone completely prevented this increased ANP release. Myocardial BNP release during regional ischaemia and reperfusion was not different with or without naloxone.
Plasma concentrations of the cardiac natriuretic peptides ANP and BNP may be of prognostic value for risk strati®cation after myocardial infarction.
1 ANP is released from granules in atrial myocytes during atrial stretch, whereas BNP is released from the ventricle. All effects mediated by natriuretic peptides, for example inhibition of sympathetic stimulation of the heart, serve to reduce arterial and venous pressures, and blood volume. They are similarly upregulated in heart failure, whereas BNP seems to be superior in detecting myocardial cell damage. 1 In our investigation, ANP increased 6-fold during regional ischaemia and 7-to 8-fold in the ®rst minute of reperfusion during myocardial stunning. Furthermore, the decreasing ANP levels over time correlated with the increased recovery of stunning. Peak ANP levels are, therefore, possibly useful in assessing the severity of myocardial stunning, especially in the absence of an elevated BNP release over time. They may also help to distinguish between stunning and postinfarction left ventricular dysfunction, because an elevated BNP release would be expected with myocardial infarction but not with myocardial stunning per se. 8 9 Furthermore, in our investigation the 10 min of coronary artery occlusion did not induce an increase for myocardial BNP release, even after 3 days of reperfusion. This supports our stunning model, and the hypothesis that isolated increased ANP levels are strongly correlated with myocardial stunning in the absence of necrosis.
Previously, we demonstrated that naloxone improved functional recovery of myocardial stunning and the ischaemic and post-ischaemic systolic left ventricular performance in conscious dogs through its action on the central nervous system. 3 EOPs are found in central areas near the cardiovascular centres of the brain, in the hypothalamus, and peripherally in the myocardium. 10 Naloxone exerts central and peripheral effects on the heart tissue itself.
11 However, the above described protective effects of naloxone 3 are probably, in the main, mediated by its antagonistic action at central opioid receptors. 12 The opioid receptor antagonist naloxone methylbromide, which unlike naloxone does not cross the blood±brain barrier, did not improve myocardial stunning in conscious dogs. 3 Central effects of naloxone are, therefore, predominant, mainly on the hypothalamus. 13 However, the central sites at which naloxone exerts this action have not been determined. EOPs, released upon myocardial ischaemia, 4 activate all central opioid receptors (m, d, k). This activation leads to sympathoinhibition and contributes to negative inotropic effects on the myocardium. Experimental data suggest that the increased endogenous opioids during heart failure act mainly on the d-receptors 13 and k-receptors. 15 Activation of these receptors decreases myocardial mechanical performance and alters regional blood¯ow distribution. Suggestions exist that the effects of non-opioid sigma receptor ligands are mediated via two receptor subtypes, of which one is positive and the other is negative inotropic. 16 From current knowledge it is unclear which effect is predominant. Pharmacological studies led to the proposal that myocardial e receptors do not play an important role, at least on cardiac rhythm. 17 In contrast, anti-arrhythmic effects mediated by d-, 18 m-, k-receptor agonists, and s-receptor mediated proarrhythmic effects are described. 17 The s opioid receptor has been demonstrated to play a major role in cardiac protection in acute instrumented animals 19 20 or isolated organs and in relation to ischaemic preconditioning. 21 In our experiments, performed in chronically instrumented dogs, the antagonistic effects of naloxone dominate. Also, we did 121 (22) 124 (25) 123 (21) 122 (13) 125 (23) 122 (32) 124 (29) 125 (36) 122 (43) 123 (33) 125 (45) 124 (39) Naloxone 126 (33) 123 (28) 127 (47) 124 (45) 126 (38) 121 (36) 118 (51) 123 (47) 122 (42) 124 (39) 125 (29) 121 (38) 119 (52) LAP (mm Hg) (595) 1189 (688) 1206 (598) 1196 (621) 1223 (567) 1263 (872) 1168 (881) 1253 (984) 95 (19) 97 (38) 96 (26) 86 (41) 85 (19) 87 (19) 91 ( Naloxone, atrial natriuretic peptide, and myocardial stunning not use ischaemic preconditioning before the ischaemic episode. Therefore, the different results may only re¯ect the different experimental settings. Acute instrumentation induces myocardial damage due to massive sympathetic stimulation and s opioid agonism mediates cardioprotective effects during acute surgical stress. This is not inevitably at variance to our results. Nevertheless, selective opioid receptor block might provide a starting-point for effectively treating the negative inotropic effects of myocardial stunning. However, further investigations in this area will be needed.
Naloxone not only improved systolic function, but also left ventricular diastolic function during regional ischaemia and myocardial stunning. Naloxone also prevented a signi®cant left atrial pressure increase and improved endocardial blood¯ow during ischaemia. These improvements explain, at least in part, the absence of an increased ANP release during ischaemia and myocardial stunning with naloxone pre-treatment. The absent ANP release, therefore, re¯ects the positive effects of naloxone on ischaemic and post-ischaemic myocardial dysfunction. No cardiovascular effects of naloxone alone, or a direct inhibitory effect on ANP secretion were found under BL conditions. This study has some limitations. First, the results obtained are restricted to dogs; there may be relevant species differences in severity and duration of the ischaemic response and its modulation by naloxone. Secondly, the study design does not allow any conclusion of possible mechanisms of the observed effect. Thirdly, a dose± response relationship regarding the protective effect of naloxone was not established.
In conclusion, ANP release, in contrast to BNP release, is enhanced during regional myocardial ischaemia and stunning in conscious dogs. Naloxone completely prevents this increased ANP release. This study is the ®rst description showing that ANP is part of the neurohumoral pro®le that occurs during myocardial stunning. 
